title: Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies.
abstract: Knowing how and when the degenerative process starts is important in neurodegenerative diseases. We have addressed this issue in fatal familial insomnia (FFI) measuring the cerebral metabolic rate of glucose (CMRglc) with 2-[18F]fluoro-2-deoxy-D-glucose PET in parallel with detailed clinical, neuropsychological examinations and polysomnography with EEG spectral analyses. Nine asymptomatic carriers of the D178N mutation, 10 non-carriers belonging to the same family, and 19 age-matched controls were studied over several years. The CMRglc as well as clinical and electrophysiological examinations were normal in all cases at the beginning of the study. Four of the mutation carriers developed typical FFI during the study but CMRglc and the clinical and electrophysiological examinations remained normal 63, 56, 32 and 21 months, respectively before disease onset. The carrier whose tests were normal 32 months before disease onset was re-examined 13 months before the onset. At that time, selective hypometabolism was detected in the thalamus while spectral-EEG analysis disclosed an impaired thalamic sleep spindle formation. Following clinical disease onset, CRMglc was reduced in the thalamus in all 3 patients examined. Our data indicate that the neurodegenerative process associated with FFI begins in the thalamus between 13 and 21 months before the clinical presentation of the disease.
authors.affiliation: Department of Neuroscience, C.N.R.-I.B.F.M., Vita-Salute San Raffaele University, Milan, Italy. pietro.cortelli@unibo.it
authors.forename: Pietro
authors.initials: P
authors.lastname: Cortelli
authors.forename: Daniela
authors.initials: D
authors.lastname: Perani
authors.forename: Pasquale
authors.initials: P
authors.lastname: Montagna
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallassi
authors.forename: Paolo
authors.initials: P
authors.lastname: Tinuper
authors.forename: Federica
authors.initials: F
authors.lastname: Provini
authors.forename: Provini
authors.initials: P
authors.lastname: Federica
authors.forename: Patrizia
authors.initials: P
authors.lastname: Avoni
authors.forename: Franco
authors.initials: F
authors.lastname: Ferrillo
authors.forename: Davide
authors.initials: D
authors.lastname: Anchisi
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Moresco
authors.forename: Ferruccio
authors.initials: F
authors.lastname: Fazio
authors.forename: Piero
authors.initials: P
authors.lastname: Parchi
authors.forename: Agostino
authors.initials: A
authors.lastname: Baruzzi
authors.forename: Elio
authors.initials: E
authors.lastname: Lugaresi
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Gambetti
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D042241:Early Diagnosis; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006579:Heterozygote; D006801:Humans; D034062:Insomnia, Fatal Familial / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D017286:Polysomnography; D049268:Positron-Emission Tomography; D011328:Prions / Q000235:genetics; D019275:Radiopharmaceuticals; D013788:Thalamus / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D011328:Prions; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18